A direct comparison of effect sizes from the clinical global impression-improvement scale to effect sizes from other rating scales in controlled trials of adult social anxiety disorder

Human Psychopharmacology

Volumn 24, Issue 1, 2009, Pages 35-40

  Hedges, Dawson W ^a   Brown, Bruce L ^a   Shwalb, David A ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Assessment scales; Clinical global impression improvement scale; Social anxiety disorder; Social phobia

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED STUDY; EFFECT SIZE; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SOCIAL PHOBIA; ADULT; COMPARATIVE STUDY; HOSPITALIZATION; PATHOPHYSIOLOGY; PHOBIA; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; STANDARD; TREATMENT OUTCOME;

ADULT; HUMANS; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 60549097404     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.989     Document Type: Article

References (33)

1. Allgulander C. 1999. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 100: 193-198.
2. Asakura S, Tajima O, Koyama T. 2007. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 10: 263-274.
3. Baldwin D, Bobes J, Stein DJ, Scharwächter I, Faure M. 1999. Paroxetine in social phobia/social anxiety disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry 175: 120-126.
4. Beneke M, Rasmus W. 1992. Clinical global impressions (ECDEU): some critical comments. Pharmacopsychiatry 25: 171-176.
5. Davidson JR, Miner CM, DeVeaugh-Geiss J, Tupler LA, Colket JT, Potts NL. 1997. The brief social phobia scale: a psychometric evaluation. Psychol Med 27: 161-166.
6. Davidson J, Yaryura-Tobias J, DuPont R, et al. 2004a. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24: 118-125.
7. Davidson JRT, Foa EB, Huppert JD, et al. 2004b. Fluoxetine, comprehensive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 61: 1005-1013.
8. Furmark T, Appel L, Michelgård A, et al. 2005. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58: 132-142.
9. Gattaz WF, Diehl A, Geuppert MS, et al. 2004. Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial. Pharmacopsychiatry 37: 279-285.
10. Gorman JM, Korotzer A, Su G. 2002. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 7 (Suppl 4): 40-44.
11. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare Publication (ADM) 76-338. National Institute of Mental Health: Rockville, MD.
12. Guy W. 2000. Clinical global impressions (CGI) scale. In Handbook of Psychiatric Measures, Rush AJ (ed). American Psychiatric Association: Washington, DC; 100-102.
13. Hedges LV, Olkin I. 1985. Statistical Methods for Meta-analysis. Academic Press: New York, NY.
14. Heimberg RG, Horner KH, Juster HR, et al. 1999. Psychometric properties of the Liebowitz social anxiety scale. Psychol Med 29: 199-212.
15. Kasper S, Stein DJ, Loft H, Nil R. 2005. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186: 222-226.
16. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. 2002. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 22: 257-262.
17. Lader M, Stender K, Bürger V, Nil R. 2004. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: ransomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19: 241-248.
18. Leon AC. 2005. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments. J Clin Psychiatry 65: 1511-1514.
19. Leon AC, Shear MK, Klerman GL, Portera L, Rosenbaum JF, Goldenberg I. 1993. A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression. J Clin Psychopharmacol 13: 327-331.
20. Lepola U, Bergtholdt B, St., Lambert J, Davy KL, Ruggiero L. 2004. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psych 65: 222-229.
21. Liebowitz RM, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. 2002. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63: 66-74.
22. Liebowitz MR, DeMartinis NA, Weihs K, et al. 2003. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64: 785-792.
23. Sheehan DV. 1983. The Anxiety Disease. Scribner: New York, NY.
24. Sheehan DV, Harnett-Sheehan K, Raj BA. 1996. The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3): 89-95.
25. Silva R, Tilker HA, Cecil JT, et al. 2004. Open-label study of dexmethyphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 14: 555-563.
26. Sprott DA. 1973. Normal likelihoods and their relation to large sample theory of estimation. Biometrika 60: 457-465.
27. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. 1998. Paroxetine treatment of generalized social phobia (social anxiety disorder). JAMA 280: 708-713.
28. Stein MB, Fyer AJ, Davidson JRT, Pollack MH, Wiita B. 1999. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156: 756-760.
29. Stein DJ, Kasper S, Wreford Anderson E, Nil R, Lader M. 2004. Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. Depress Anxiety 20: 175-181.
30. Steiner M, Allgulander C, Ravindran A, Kosar H, Burt T, Austin C. 2005. Gender differences in clinical presentation of generalized anxiety disorder. Hum Psychopharmacol 20: 3-13.
31. Van Ameringen MA, Lane RM, Walker JR, et al. 2001. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158: 275-281.
32. Watson D, Friend R. 1969. Measurement of social-evaluative anxiety. J Consult Clin Psychol 33: 448-457.
33. Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM. 2004. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized anxiety disorder. J Clin Psychopharmacol 24: 49-55.